15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English Vaccitech 将在 VTP-300 上举办虚拟 KOL 活动,这是慢性 ...
查看: 330|回复: 2
go

Vaccitech 将在 VTP-300 上举办虚拟 KOL 活动,这是慢性乙型肝炎 ( [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2022-1-14 18:08 |只看该作者 |倒序浏览 |打印
Vaccitech 将在 VTP-300 上举办虚拟 KOL 活动,这是慢性乙型肝炎 (CHB) 感染的潜在功能性治疗方法,以及更广泛的 CHB 治疗前景
Vaccitech(英国)有限公司
2022 年 1 月 14 日星期五上午 8:34·4 分钟阅读

网络直播将于 1 月 25 日美国东部标准时间上午 8:30 进行

英国牛津,2022 年 1 月 13 日 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”) 是一家从事发现和开发新型免疫疗法和疫苗的临床阶段生物制药公司,今天宣布将举办虚拟 Key关于 VTP-300 的意见领袖 (“KOL”) 活动正在开发中,作为慢性乙型肝炎 (CHB) 感染的功能性治愈疗法的关键组成部分,以及更广泛的 CHB 治疗领域。该活动将于美国东部时间 1 月 25 日上午 8:30 进行网络直播。

特邀演讲者:

    Kaushik Agarwal 博士,国王学院医院肝脏研究所肝病学顾问和移植医师,病毒性肝炎服务负责人,以及 NIHR 南伦敦临床研究网络主任。

    Henry L. Y. Chan 博士,胃肠病学和肝病学部主任,消化疾病研究所、肝脏健康中心和全球参与办公室主任。陈博士亦为中大医学院对外事务助理院长及中大肠胃病理学硕士课程主任。

Vaccitech的Virtual KOL Event详情如下:

    2022 年 1 月 25 日,星期二,美国东部标准时间上午 8:30 - 美国东部标准时间上午 10:00

    要加入网络直播,请访问公司网站投资者关系页面的活动部分:https://investors.vaccitech.co.uk/news-and-events/events

    网络广播的重播将在同一地点提供

关于 Vaccitech plc

Vaccitech(“公司”)是一家临床阶段的生物制药公司,致力于发现和开发用于治疗和预防传染病、癌症和自身免疫性疾病的新型免疫疗法和疫苗。该公司的专有平台包括改良的猿腺病毒载体,称为 ChAdOx1 和 ChAdOx2,经过充分验证的改良 Vaccinia Ankara,或 MVA,所有这些都缺乏在人类中复制的能力,以及基于 SNAPvax™ 和 Syntholytic™ 聚合物的平台。该公司在实体瘤、病毒感染、自身免疫和预防性病毒疫苗计划方面拥有广泛的临床和临床前阶段治疗计划。 Vaccitech 与牛津大学共同发明了一种 COVID-19 疫苗,现已获准在许多地区使用,并通过牛津大学创新 (OUI) 在全球独家授权给阿斯利康 (AstraZeneca)。 Vaccitech 有权从 OUI 从阿斯利康获得的里程碑和特许权使用费收入的一部分。

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2022-1-14 18:08 |只看该作者
Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape
Vaccitech (UK) Limited
Fri, January 14, 2022, 8:34 AM·4 min read

Live webcast will be at 8:30 a.m. EST on January 25

OXFORD, United Kingdom, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a virtual Key Opinion Leader (“KOL”) event on VTP-300, in development as a key component of a functional cure therapy for chronic hepatitis B (CHB) infection, and the broader CHB therapeutics landscape. The event will be webcast live on January 25th at 8:30 a.m. EST.

Featured speakers:

    Dr. Kaushik Agarwal, consultant hepatologist and transplant physician at the Institute of Liver Studies at King’s College Hospital, Viral Hepatitis Service lead, and Director of the NIHR South London Clinical Research Network.

    Dr. Henry L. Y. Chan, head of the Division of Gastroenterology and Hepatology, Director of the Institute of Digestive Disease, the Center for Liver Health, and the Office of Global Engagement. Dr. Chan is also the Assistant Dean of External Affairs for the Faculty of Medicine at CUHK and the Course Director for the Master of Science in Gastroenterology at CUHK.

Vaccitech’s Virtual KOL Event details are as follows:

    Tuesday, January 25th, 2022, 8:30 a.m. EST – 10:00 a.m. EST

    To join the webcast, please visit the Events section of the Investor Relations page of the Company’s website at: https://investors.vaccitech.co.uk/news-and-events/events

    A replay of the webcast will be available at the same location

About Vaccitech plc

Vaccitech (“the Company”) is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines for the treatment and prevention of infectious disease, cancer, and autoimmune disease. The company’s proprietary platforms comprise modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, the well-validated Modified Vaccinia Ankara, or MVA, all of which lack the ability to replicate in humans, and the SNAPvax™ and Syntholytic™ polymer-based platforms. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors, viral infections, autoimmunity, and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

Rank: 10Rank: 10Rank: 10

现金
20661 元 
精华
帖子
12793 
注册时间
2013-12-29 
最后登录
2024-11-3 
3
发表于 2022-1-14 19:45 |只看该作者
本帖最后由 newchinabok 于 2022-1-14 19:45 编辑

乙肝患者在再10年,都老龄化了,新药还有什么意义
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-6 09:31 , Processed in 0.012900 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.